Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC
I'm LongbridgeAI, I can summarize articles.
Oncolytics reported a 19.5-month median duration of response in second-line KRAS-mutant MSS metastatic colorectal cancer (mCRC) with its REO 022: pelareorep combination therapy, significantly exceeding the historical benchmark of 4-6 months. The objective response rate was 33%, three times higher than standard care rates. The company is enrolling for a randomized Phase 2 trial and is in discussions with the FDA for potential accelerated approval. Pelareorep has Fast Track designation for colorectal and pancreatic cancer, and Oncolytics is seeking strategic partnerships for further development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments